Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ProQR Therapeutics NV's annualized net income for the quarter that ended in Mar. 2026 was MXN-1,116.0 Mil. ProQR Therapeutics NV's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN912.4 Mil. Therefore, ProQR Therapeutics NV's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -122.31%.
The historical rank and industry rank for ProQR Therapeutics NV's Return-on-Tangible-Equity or its related term are showing as below:
MEX:PRQRN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -100.77 Med: -62.32 Max: -42.17
Current: -79.92
During the past 13 years, ProQR Therapeutics NV's highest Return-on-Tangible-Equity was -42.17%. The lowest was -100.77%. And the median was -62.32%.
MEX:PRQRN's Return-on-Tangible-Equity is ranked worse than 67.16% of 1206
companies
in the Biotechnology industry
Industry Median: -42.53
vs MEX:PRQRN: -79.92
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ProQR Therapeutics NV Return-on-Tangible-Equity Related Terms
ProQR Therapeutics NV Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ProQR Therapeutics NV's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRQRN vs GALT, HRTX, PLYX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -122.31% mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Return-on-Tangible-Equity of -122.31% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ProQR Therapeutics NV and its competitors. According to the industry distribution chart, ProQR Therapeutics NV ranks #810 out of 1206 companies in the Biotechnology industry, placing it in the top 67.2%.
Is ProQR Therapeutics NV's Return-on-Tangible-Equity too high?
ProQR Therapeutics NV's current Return-on-Tangible-Equity is -122.31%. Based on the distribution chart, ProQR Therapeutics NV ranks #810 out of 1206 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Return-on-Tangible-Equity compare to GALT and HRTX?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #810 out of 1206 companies for Return-on-Tangible-Equity. This places ProQR Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Return-on-Tangible-Equity is -122.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Return-on-Tangible-Equity of -122.31%. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current Return-on-Tangible-Equity is -122.31%. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Return-on-Tangible-Equity is -122.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.
Key valuation signals for MEX:PRQRN:
Return-on-Tangible-Equity: -122.31%
GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score
Get the complete analysis for MEX:PRQRN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRQRN has been successfully added to your 
